BOSTON & MONTREAL, December 30, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Pfizer Inc. today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus ...

BBC Sport explains how the cold temperatures can effect a football team's pre-game approach and in-game strategy.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition success ...

Complete response at either 3 or 6 months occurred in 74.5%. The median duration of response has not yet been reached, but exceeds 27 months. Intravesical cretostimogene grenadenorepvec leads to ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

Pembrolizumab is under clinical development by Merck and currently in Phase II for Anal Cancer. According to GlobalData, Phase II drugs for Anal Cancer have a 19% phase transition success rate (PTSR) ...

Dating to the late Roman period, a stunning, figurative mosaic, found buried under just 50cm of soil and featuring the rare ...